$IMRA News
Last published 1y ago
- 1y agoICOIIGMEIMRAIMSTBitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGMEBusiness WireBitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per
- 3y agoIMRAImara Announces Stockholder Approval of Merger With EnlivenGlobeNewswire-- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today
- 4y agoIMRAEnliven Therapeutics and Imara Announce Merger AgreementGlobeNewswireMerger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300
- 4y agoIMRASelective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction - NCT05312021ClinicalTrials.govChange in NT-proBNP, To evaluate the safety and tolerability in IMR-687 versus placebo (TEAEs: Treatment-emergent adverse events, Change in Baseline to Week 16 in the Kansas City Cardiomyopathy Questionnaire overall summary score, (and 17 more...)
- 4y agoIMRAImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-ThalassemiaGlobeNewswireInterim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population Interim results in Forte trial for beta-thal
- 4y agoIMRAImara Reports Full Year 2021 Financial Results and Business HighlightsGlobeNewswireCompleted enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease t
- 4y agoIMRAImara to Webcast Conference Call of Full Year 2021 Financial Results and Business HighlightsGlobeNewswireBOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious
- 4y agoIMRAImara to Present at 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious d
- 4y agoIMRAImara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)GlobeNewswireExpanding patient base and potential of Imara's small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expressionfor targeted approach to a heterogeneou
- 4y agoIMRAImara to Present at the H.C. Wainwright BioConnect 2022 Virtual ConferenceGlobeNewswireBOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobi
- 4y agoIMRAImara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021GlobeNewswireOral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 activation of Nrf2 increases HbF and F-cells, reduces V
- 4y agoIMRAImara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021GlobeNewswireBOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobi
- 4y agoIMRAImara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell DiseaseGlobeNewswirePrimary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on track for interim analysis of VOC rates in first quarte
- 4y agoIMRAImara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemiaGlobeNewswirePositive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Ima
- 5y agoIMRAImara Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewswireInterim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 act
- 5y agoIMRAImara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)GlobeNewswirePreclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical De
- 5y agoIMRAImara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business HighlightsGlobeNewswireBOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobi
- 5y agoIMRAImara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021GlobeNewswireTovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation provides first look at IMR-261, a novel oral Nrf2 activa
- 5y agoIMRAImara to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglob
- 5y agoIMRAImara to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglob
- 5y agoIMRAImara Reports Second Quarter 2021 Financial Results and Business HighlightsGlobeNewswireAccelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at the European Hematology Association (EHA) Annual Congr
- 5y agoIMRAImara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell DiseaseGlobeNewswireBOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobi
- 5y agoIMRAImara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business HighlightsGlobeNewswireBOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobi
- 5y agoCFMSCYTKIMRAPSAC+1Thinking about buying stock in Cytokinetics, Property Solutions Acquisition, Imara, ConforMIS, or Sesen Bio?PR NewswireNEW YORK, July 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYTK, PSAC, IMRA, CFMS, and SESN. T
- 5y agoIMRAImara Announces Pricing of Public OfferingGlobeNewswireBOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the "Company") (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disord
- 5y agoIMRAImara Announces Launch of Proposed Public OfferingGlobeNewswireBOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the "Company") (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disord
- 5y agoIMRAImara Announces Appointment of Laura A. Williams, M.D., MPH to Board of DirectorsGlobeNewswireBOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobi
- 5y agoIMRAImara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood DisordersGlobeNewswireBOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobi
- 5y agoIMRAImara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual CongressGlobeNewswireFinal data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response
- 5y agoIMRAImara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual CongressGlobeNewswireOral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ET BOSTON, June 04, 2021 (GLOBE NEWSW
- 5y agoIMRAImara Reports First Quarter 2021 Financial Results and Business HighlightsGlobeNewswireOn-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial
- 5y agoIMRAImara Inc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 11, 2021 / Imara Inc (NASDAQ:IMRA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a replay of
- 5y agoIMRAImara to Webcast Conference Call of First Quarter 2021 Financial Results and Business HighlightsGlobeNewswireBOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin
- 5y agoIMRAImara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood DisordersGlobeNewswireBOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 5y agoIMRANew patent application published for: Pde9 Inhibitors for Treatment of Peripheral DiseasesUS Patent Applications (USPTO)( 1 of 1 )
- 5y agoIMRAImara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-ThalassemiaGlobeNewswireIndependent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower...
- 5y agoIMRAImara Reports Full Year 2020 Financial Results and Business HighlightsGlobeNewswireSignificant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical...
- 5y agoIMRAImara to Webcast Conference Call of Full Year 2020 Financial Results and Business HighlightsGlobeNewswireBOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 5y agoIMRAImara to Present at SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewswireBOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 5y agoIMRAImara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical OfficerGlobeNewswireBOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 5y agoIMRAImara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell DiseaseGlobeNewswirePromising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement...
- 5y agoIMRAImara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and ExpositionGlobeNewswirePreliminary data as of August 2020 from ongoing Phase 2a open label extension trial showed increases in HbF percentage and F-cells after approximately six months of treatment Case reports showed...
- 5y agoIMRAImara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and ExpositionGlobeNewswireBOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 5y agoIMRAImara Announces the Appointment of Lynette Hopkinson as Senior Vice President of RegulatoryGlobeNewswireBOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 6y agoIMRAImara Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewswirePatient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...
- 6y agoIMRAImara to Webcast Conference Call of Third Quarter Financial ResultsGlobeNewswireBOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 6y agoIMRAImara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-ThalassemiaGlobeNewswireBOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 6y agoIMRAImara to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 6y agoIMRAImara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell DiseaseGlobeNewswireBOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
- 6y agoIMRAIMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts